The Monarch eTNS® System is the First FDA Cleared Device for Treating Pediatric ADHD.
The Monarch eTNS System is indicated for the treatment of pediatric Attention Deficit Hyperactivity Disorder (ADHD) as a monotherapy in patients ages 7 through 12 years old who are not currently taking prescription ADHD medications. The device is used for patient treatment by prescription only and is intended to be used in the home under the supervision of a caregiver during periods of sleep.
The most common side effects observed with eTNS use are: drowsiness, an increase in appetite, trouble sleeping, teeth clenching, headache and fatigue. No serious adverse events have been associated with use of the device. Please consult the instructions for use for additional information.
Latest News
March 01, 2023 NeuroSigma Announces New Telehealth Option for Patients and Caregivers Interested in eTNS for Pediatric ADHD
January 31, 2023 NeuroSigma Announces Strategic Digital Marketing Partnership with Data360
November 08, 2022 NeuroSigma Announces that Enrollment Commences in Two Large, Double-Blind Trials of eTNS for Pediatric ADHD
September 27,2022 NeuroSigma Announces Receipt of Permanent HCPCS Codes from CMS for Monarch eTNS System
February 22,2022 NeuroSigma Receives FDA Breakthrough Device Designation for Monarch eTNS System®
January 25,2022 Ignis Therapeutics Licenses NeuroSigma eTNS Technology for ADHD in a Significant China Licensing Transaction
January 11,2022 NeuroSigma Announces Promotion of Dr. Colin Kealey to President
